Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor
Clinical trial NCT02500550 · COMPLETED
Trial details
- NCT number
- NCT02500550
- Sponsor
- Kiadis Pharma
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-10-09
- Primary completion
- 2018-07-01
- Enrollment
- 15
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.